DocGo Inc.

DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.

DocGo Inc. trades as DCGO on NASDAQ. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $322.20M of revenue and -$182.40M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

DocGo Inc. can be compared against peers such as Coya Therapeutics, Inc., Immix Biopharma, Inc., Microbot Medical Inc., MacroGenics, Inc., InspireMD, Inc., Ovid Therapeutics Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $55.24M, beta of 1.02, and return on equity of -126.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

DCGO currently shows total debt of $29.18M and beta of 1.02. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 4 (2026-05-14 00:00:00), 10-Q (2026-05-11 00:00:00), 8-K (2026-05-11 00:00:00), ARS (2026-04-22 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.docgo.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.